INDGN

Indegene Share Price

 

 

Invest in Indegene with 3.27X leverage

Invest with MTF

Performance

  • Low
  • ₹508
  • High
  • ₹529
  • 52 Week Low
  • ₹499
  • 52 Week High
  • ₹735
  • Open Price₹527
  • Previous Close₹530
  • Volume511,121

Investment Returns

  • Over 1 Month -8.53%
  • Over 3 Month -8.32%
  • Over 6 Month -3.95%
  • Over 1 Year -23.71%

Smart Investing Starts Here Start SIP with Indegene for Steady Growth!

Invest Now

Indegene Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.2
  • PEG Ratio
  • 1.4
  • Market Cap Cr
  • 12,559
  • P/B Ratio
  • 5.3
  • Average True Range
  • 13.62
  • EPS
  • 18.56
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -6.06
  • RSI
  • 35.6
  • MFI
  • 68.47

Indegene Financials

Indegene Technicals

EMA & SMA

Current Price
₹523.10
-7.05 (-1.33%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹544.16
  • 50 Day
  • ₹554.06
  • 100 Day
  • ₹561.83
  • 200 Day
  • ₹571.38

Resistance and Support

519.82 Pivot Speed
  • R3 552.88
  • R2 540.77
  • R1 531.93
  • S1 510.98
  • S2 498.87
  • S3 490.03

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indegene is a global healthcare solutions company providing commercial, medical, and digital transformation services to life sciences companies. It helps pharmaceutical, biotech, and healthcare organizations enhance patient outcomes through data-driven strategies and innovative technology solutions.

Indegene Ltd has an operating revenue of Rs. 3,041.00 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 27% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 108 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indegene Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-30 Quarterly Results
2025-07-31 Quarterly Results
2025-04-28 Audited Results & Final Dividend
2025-01-30 Quarterly Results & Others To consider other business matters. per share(100%)Final Dividend
2024-10-28 Quarterly Results
Date Purpose Remarks
2025-06-13 FINAL Rs.2.00 per share(100%)Final Dividend
View Indegene Dividend History Arrow

Indegene F&O

Indegene Shareholding Pattern

0%
3.07%
0.01%
11.3%
13.28%
72.34%

Indegene FAQs

Indegene share price is ₹523 As on 08 November, 2025 | 06:35

The Market Cap of Indegene is ₹12558.5 Cr As on 08 November, 2025 | 06:35

The P/E ratio of Indegene is 28.2 As on 08 November, 2025 | 06:35

The PB ratio of Indegene is 5.3 As on 08 November, 2025 | 06:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23